Shares of ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF – Get Free Report) fell 7.9% during trading on Wednesday . The company traded as low as $1.46 and last traded at $1.51. Approximately 341,163 shares were traded during mid-day trading, an increase of 1,578% from the average session volume of 20,327 shares. The stock had previously closed at $1.64.
ImmunoPrecise Antibodies Price Performance
The business’s 50-day moving average is $1.50 and its two-hundred day moving average is $1.53.
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) is a Canada-based contract research organization specializing in the discovery and development of therapeutic antibodies. The company provides a full suite of preclinical research services, from target validation and lead identification through to humanization and optimization. Its capabilities encompass hybridoma, phage display, single B cell sorting and next-generation sequencing platforms to accelerate antibody candidate selection and characterization.
ImmunoPrecise serves biopharmaceutical and biotechnology partners worldwide, offering customized solutions for projects in immuno-oncology, infectious diseases, autoimmunity and other therapeutic areas.
See Also
- Five stocks we like better than ImmunoPrecise Antibodies
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
